LEAD Therapeutics presents new antibiotic with potent activity against drug resistant bacteria at the 49th ICAAC
SAN BRUNO, Calif. & SHANGHAI–(BUSINESS WIRE)–LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria. LEAD will present the new glycopeptide antibiotic, LT-29, for the first time at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). LT-29 is in preclinical development to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.